HSF1/AMPK activator 1

HSF1/AMPK activator 1 (Compound 11) (0-20 μM; 48 h) potently inhibits fibronectin expression in human LX-2 cells treated with TGF-β1, with an IC₅₀ of 0.7 μM. At 10 μM for 48 h, it shows an inhibition rate of 91.6 ± 3.8% without associated cytotoxicity^[1].
HSF1/AMPK activator 1 (0-80 μM; 48 h) exhibits no cytotoxicity in human LX-2 and HEK-293 cells even at concentrations as high as 80 μM^[1].
HSF1/AMPK activator 1 (2.5-10 μM; 48 h) inhibits the proliferation of human LX-2 cells treated with TGF-β1 in a dose-dependent manner^[1].
HSF1/AMPK activator 1 (2.5-10 μM; 48 h) dose-dependently reduces the expression of fibronectin, type I collagen and α-smooth muscle actin (α-SMA)-fibrosis markers-at both transcriptional and translational levels in TGF-β1-treated human LX-2 cells^[1].
HSF1/AMPK activator 1 (2.5-10 μM; 48 h) inhibits TGF-β1-induced phosphorylation and nuclear translocation of Smad3 in a dose-dependent manner in human LX-2 cells, thereby suppressing the TGF-β1/Smad signaling pathway^[1].
HSF1/AMPK activator 1 (2.5-10 μM; 48 h) inhibits proliferation, fibrosis and the TGF-β1/Smad signaling pathway in TGF-β1-treated mouse hepatic stellate cells in a dose-dependent manner^[1].
HSF1/AMPK activator 1 (2.5-10 μM; 48 h) dose-dependently activates the HSF1/AMPK metabolic axis in TGF-β1-treated human LX-2 cells and mouse hepatic stellate cells, increases the phosphorylation levels of AMPK and HSF1, and promotes the nuclear localization of activated HSF1^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.